Medicines Formulary - search results for ""

Search results for ""

Drug name	NICE TAs	Comments	Subchapter
Simple linctus paediatric			3.9
Simvastatin tablets		MHRA advice regarding high dose simvastatin (May 2010): • Simvastatin 80 mg should be considered only in patients with severe hypercholesterolaemia and high risk of cardiovascular complications who have not achieved their treatment goals on lower doses, when the benefits are expected to outweigh the potential risks • Prescribers treating patients who are taking simvastatin 80 mg or who are being considered for an up-titration to that dose may need to review their treatment during their next visit, to take into account the new evidence • Patients who are currently taking simvastatin 80 mg should not stop taking their medicine. However, they should be advised to contact their doctor immediately if they experience unexplained muscle pain, tenderness, or weakness • Please report suspected adverse reactions with medicines, including statins, to us via the Yellow Card Scheme (www.yellowcard.gov.uk)	2.12
Siponimod (Mayzent®)	TA656 - Siponimod for treating secondary progressive multiple sclerosis		8.1
Sirolimus solution	TA85 - Immunosuppressive therapy for renal transplantation in adults	New post-transplant	8.2
Sirolimus solution	TA85 - Immunosuppressive therapy for renal transplantation in adults	Post-transplant pre 2015	8.2
Sirolimus tablets	TA85 - Immunosuppressive therapy for renal transplantation in adults	New post-transplant	8.2
Sirolimus tablets	TA85 - Immunosuppressive therapy for renal transplantation in adults	Post-transplant pre 2015	8.2
Sitagliptin tablets			6.1
Skin prick test		Hospital use only	3.4
Smallpox vaccine			14.4

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
Next page
Last page

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.